Neuronal Death in Alzheimer's Disease and Therapeutic Opportunities

Overview

Journal J Cell Mol Med

Specialties Cell Biology
Molecular Biology

Date 2009 Sep 4

PMID 19725918

Citations 42

Authors

Rossen Donev

Martin Kolev

Bruno Millet

Johannes Thome

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is an age-related neurodegenerative disease that affects approximately 24 million people worldwide. A number of different risk factors have been implicated in AD; however, neuritic (amyloid) plaques are considered as one of the defining risk factors and pathological hallmarks of the disease. In the past decade, enormous efforts have been devoted to understand the genetics and molecular pathogenesis leading to neuronal death in AD, which has been transferred into extensive experimental approaches aimed at reversing disease progression. Modern medicine is facing an increasing number of treatments available for vascular and neurodegenerative brain diseases, but no causal or neuroprotective treatment has yet been established. Almost all neurological conditions are characterized by progressive neuronal dysfunction, which, regardless of the pathogenetic mechanism, finally leads to neuronal death. The particular emphasis of this review is on risk factors and mechanisms resulting in neuronal loss in AD and current and prospective opportunities for therapeutic interventions. This review discusses these issues with a view to inspiring the development of new agents that could be useful for the treatment of AD.

Citing Articles

Gallic acid ameliorates LPS-induced memory decline by modulating NF-κB, TNF-α, and Caspase 3 gene expression and attenuating oxidative stress and neuronal loss in the rat hippocampus.

Dastan M, Rajaei Z, Sharifi M, Salehi H Metab Brain Dis. 2024; 40(1):12.

PMID: 39556267 DOI: 10.1007/s11011-024-01441-5.

Long-term radiofrequency electromagnetic fields exposure attenuates cognitive dysfunction in 5×FAD mice by regulating microglial function.

Son Y, Park H, Jeong Y, Choi H, Kim N, Lee H Neural Regen Res. 2023; 18(11):2497-2503.

PMID: 37282482 PMC: 10360091. DOI: 10.4103/1673-5374.371379.

Extract of Nakai Leaf Ameliorates Memory Dysfunction via Anti-inflammatory Action.

Lee S, Park S, Jang G, Lee J, Moon M, Ji Y Int J Mol Sci. 2023; 24(6).

PMID: 36982837 PMC: 10052554. DOI: 10.3390/ijms24065765.

The Role of Tryptophan Metabolism in Alzheimer's Disease.

Savonije K, Weaver D Brain Sci. 2023; 13(2).

PMID: 36831835 PMC: 9954102. DOI: 10.3390/brainsci13020292.

Impact of impaired cerebral blood flow autoregulation on cognitive impairment.

Wang S, Tang C, Liu Y, Border J, Roman R, Fan F Front Aging. 2022; 3:1077302.

PMID: 36531742 PMC: 9755178. DOI: 10.3389/fragi.2022.1077302.

References

Gilman S, Koller M, Black R, Jenkins L, Griffith S, Fox N . Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64(9):1553-62. DOI: 10.1212/01.WNL.0000159740.16984.3C. View

Kwak S, Masaki T, Ishiura S, Sugita H . Multicatalytic proteinase is present in Lewy bodies and neurofibrillary tangles in diffuse Lewy body disease brains. Neurosci Lett. 1991; 128(1):21-4. DOI: 10.1016/0304-3940(91)90751-e. View

Winblad B, Poritis N . Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 2000; 14(2):135-46. DOI: 10.1002/(sici)1099-1166(199902)14:2<135::aid-gps906>3.0.co;2-0. View

Morgan B, Harris C . Complement therapeutics; history and current progress. Mol Immunol. 2003; 40(2-4):159-70. DOI: 10.1016/s0161-5890(03)00111-1. View

Rakover I, Arbel M, Solomon B . Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels. Neurodegener Dis. 2007; 4(5):392-402. DOI: 10.1159/000103250. View

Bate C, Veerhuis R, Eikelenboom P, Williams A . Neurones treated with cyclo-oxygenase-1 inhibitors are resistant to amyloid-beta1-42. Neuroreport. 2003; 14(16):2099-103. DOI: 10.1097/00001756-200311140-00018. View

Selkoe D, Schenk D . Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol. 2002; 43:545-84. DOI: 10.1146/annurev.pharmtox.43.100901.140248. View

Hamada Y, Ohta H, Miyamoto N, Yamaguchi R, Yamani A, Hidaka K . Novel non-peptidic and small-sized BACE1 inhibitors. Bioorg Med Chem Lett. 2008; 18(5):1643-7. DOI: 10.1016/j.bmcl.2008.01.056. View

Klajnert B, Cortijo-Arellano M, Cladera J, Bryszewska M . Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem Biophys Res Commun. 2006; 345(1):21-8. DOI: 10.1016/j.bbrc.2006.04.041. View

10.

Searfoss G, Jordan W, Calligaro D, Galbreath E, Schirtzinger L, Berridge B . Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem. 2003; 278(46):46107-16. DOI: 10.1074/jbc.M307757200. View

11.

Sano M, Ernesto C, Thomas R, Klauber M, Schafer K, Grundman M . A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997; 336(17):1216-22. DOI: 10.1056/NEJM199704243361704. View

12.

Schofield P, Tang M, Marder K, Bell K, Dooneief G, Chun M . Alzheimer's disease after remote head injury: an incidence study. J Neurol Neurosurg Psychiatry. 1997; 62(2):119-24. PMC: 486721. DOI: 10.1136/jnnp.62.2.119. View

13.

Weggen S, ERIKSEN J, Das P, Sagi S, Wang R, Pietrzik C . A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001; 414(6860):212-6. DOI: 10.1038/35102591. View

14.

Janus C, Pearson J, McLaurin J, Mathews P, Jiang Y, Schmidt S . A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2001; 408(6815):979-82. DOI: 10.1038/35050110. View

15.

Miyagawa S, Shirakura R, Matsumiya G, Fukushima N, Nakata S, Matsuda H . Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT175. Transplantation. 1993; 55(4):709-13. DOI: 10.1097/00007890-199304000-00004. View

16.

Wong G, Manfra D, Poulet F, Zhang Q, Josien H, Bara T . Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004; 279(13):12876-82. DOI: 10.1074/jbc.M311652200. View

17.

Mucke L, Masliah E, Yu G, Mallory M, Rockenstein E, Tatsuno G . High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci. 2000; 20(11):4050-8. PMC: 6772621. View

18.

Cowburn R, Popescu B, Ankarcrona M, Dehvari N, Cedazo-Minguez A . Presenilin-mediated signal transduction. Physiol Behav. 2007; 92(1-2):93-7. DOI: 10.1016/j.physbeh.2007.05.053. View

19.

Selkoe D . Cell biology of the amyloid beta-protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol. 1994; 10:373-403. DOI: 10.1146/annurev.cb.10.110194.002105. View

20.

Melnikova I . Therapies for Alzheimer's disease. Nat Rev Drug Discov. 2007; 6(5):341-2. DOI: 10.1038/nrd2314. View